Diplomat Pharmacy (Diplomat Pharmacy) EBITDA Margin % : -11.58% (As of Sep. 2019)

View and export this data going back to 2014. Start your Free Trial

What is Diplomat Pharmacy EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Diplomat Pharmacy's EBITDA for the three months ended in Sep. 2019 was $-151 Mil. Diplomat Pharmacy's Revenue for the three months ended in Sep. 2019 was $1,301 Mil. Therefore, Diplomat Pharmacy's EBITDA margin for the quarter that ended in Sep. 2019 was -11.58%.

Diplomat Pharmacy EBITDA Margin % Historical Data

The historical data trend for Diplomat Pharmacy's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diplomat Pharmacy EBITDA Margin % Chart

Diplomat Pharmacy Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

EBITDA Margin %

Get a 7-Day Free Trial

0.90

2.29

2.10

1.90

-3.07

Diplomat Pharmacy Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
EBITDA Margin %	Get a 7-Day Free Trial															2.52	-19.74	1.43	-10.00	-11.58

Competitive Comparison of Diplomat Pharmacy's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Diplomat Pharmacy's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diplomat Pharmacy's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Diplomat Pharmacy's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Diplomat Pharmacy's EBITDA Margin % falls into.

Diplomat Pharmacy EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Diplomat Pharmacy's EBITDA Margin % for the fiscal year that ended in Dec. 2018 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2018 )	/	Revenue (A: Dec. 2018 )
	=	-168.546	/	5492.524
	=	-3.07 %

Diplomat Pharmacy's EBITDA Margin % for the quarter that ended in Sep. 2019 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2019 )	/	Revenue (Q: Sep. 2019 )
	=	-150.649	/	1301.197
	=	-11.58 %

Diplomat Pharmacy (NYSE:DPLO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Diplomat Pharmacy EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Diplomat Pharmacy's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Diplomat Pharmacy (Diplomat Pharmacy) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Diplomat Pharmacy Inc (NYSE:DPLO) » Definitions » EBITDA Margin %

Traded in Other Exchanges

N/A

Address

4100 South Saginaw Street, Flint, MI, USA, 48507

Website

http://www.diplomat.is

Diplomat Pharmacy Inc. is active in the U.S. healthcare sector. It provides specialty pharmacy and infusion services, including pharmacy solutions for chronic diseases. The company has two main segments: specialty pharmacy and pharmacy benefit management. Its specialty pharmacy segment offers solutions to dispense, deliver, and dose prescription drugs. The pharmacy benefit management segment offers services to help control pharmacy benefit dollars and maximize quality of care. It derives most of its revenue through prescription drug sales in the United States.

Executives

Brian T Griffin	director, officer: Chairman and CEO
David C Dreyer	director	C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Shawn Tomasello	director	C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Regina M. Benjamin	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Benjamin Wolin	director	C/O EVERYDAY HEALTH, INC., 345 HUDSON STREET, 16TH FLOOR, NEW YORK NY 10014
Jeffrey G Park	director	C/O DIPLOMAT PHARMACY, INC., 4100 S. SAGINAW ST., FLINT MI 48507
Sean Whelan	director, officer: Chief Financial Officer	C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Jeffrey M Rowe	director, officer: EVP of Operations	C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018